Bispecific antibodies (BsAbs) are being researched for the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma. These novel engineered antibodies work by attaching to two different antigens, either on separate cells—connecting a cancer cell to an immune system cell—or on an individual cell, disrupting the cancer’s signaling pathways. Specifically, T-cell engaging bispecific antibodies (T-biAbs) have shown promise in redirecting and activating T cells against these types of cancers.
Clinical trials and studies have demonstrated promising results, with some patients achieving complete or partial remission, particularly in the treatment of blood cancers. While BsAbs are also being researched for use against solid tumors, their most promising results so far have been in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma.
What is the success rate of bispecific antibody therapy for cancer?
The success rate of bispecific antibody (BsAb) therapy for cancer varies depending on the specific type of cancer and the particular BsAb used. Clinical studies have demonstrated promising results, with some patients achieving complete or partial remission, particularly in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma.
For example, a phase I/II clinical trial presented at the AACR Annual Meeting 2023 reported an overall response rate of 65.1% in patients with multiple myeloma treated with a specific BsAb.
Bispecific Antibodies treatment is available at Sheba hospital in Israel.
Sources:
NIH- Bispecific antibodies for cancer therapy
MD Anderson: Bispecifics antibodies: The next big thing in lymphoma treatment.
US FDA
Frontiers in immunology
